A similar phenomenon has been described in lung cancer, whereby cells under oxidative stress are resistant to tyrosine kinase inhibitors, including erlotinib, due to abnormal EGFR activation and trafficking that results from its localization to ceramide-rich rafts [39]. Here, EGFR is linked to lung cancer.